LincRNA-p21 acts as a chemosensitizer for distinguishing the chemosensitivity of mutant p53-expressing breast cancer

First Author / 第一作者

Yu-Hao He

Institution / 單位

Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan

Audio / 音訊檔

Author Group / 作者群

Ming-Hsin Yeh(2,3), Hsiao-Fan Chen(1,4), Ya-Ling Wei(1), Thanh Kieu Huynh(1), Dai-Wei Hu(1), Fang-Ju Cheng(1), Shu-Wei Hu(1), Yeh Chen(4,5), Ya-Jen Chang(6), and Wei-Chien Huang(1,4*)

Author Group Institution/ 作者群單位

(1)Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan; (2)Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan; (3)Institute of Medicine, School of Medicine, Chung Shan Medical University, Taichung, Taiwan; (4)Drug Development Center, China Medical University, Taichung, Taiwan; (5)Institute of New Drug Development, China Medical University, Taichung, Taiwan; (6)Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan

Category / 主題分類

Basic Research

Keyword / 關鍵字

Mutant p53、estrogen receptor、lincRNA-p21、DDB2、non-B DNA、chemotherapy

Back to list